Kochuveettil Swapna, Angeli Morales Roberto, Kaminska Alicja, Colon-Otero Gerardo
Division of Hematology & Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA.
Medical Student, University of Puerto Rico School of Medicine, San Juan, PR, USA.
Gynecol Oncol Rep. 2024 Aug 3;55:101475. doi: 10.1016/j.gore.2024.101475. eCollection 2024 Oct.
The goal of this study was to assess the safety of nab-paclitaxel in patients with ovarian cancer or endometrial cancer who had an allergic reaction to paclitaxel. We performed a retrospective review of patients with endometrial cancer or ovarian cancer with an allergic reaction to paclitaxel who were subsequently treated with nab-paclitaxel at the Mayo Clinic Florida from January 2016 to June 2023. A total of 43 patients with ovarian cancer (31) or endometrial cancer (12) and a paclitaxel allergic reaction were identified. All patients were pre-medicated against allergic reactions prior to paclitaxel and subsequent nab-paclitaxel. Allergic reactions to paclitaxel were mild in fourteen patients (33%), moderate in twenty-five patients (58%) and severe in four (9%) patients. None of the 43 patients had an allergic reaction to subsequent nab-paclitaxel. Our data suggests that the administration of nab-paclitaxel to endometrial cancer or ovarian cancer patients with allergic reactions to paclitaxel is safe and should be considered a preferable treatment option in this clinical situation.
本研究的目的是评估在对紫杉醇过敏的卵巢癌或子宫内膜癌患者中使用白蛋白结合型紫杉醇的安全性。我们对2016年1月至2023年6月在佛罗里达州梅奥诊所接受白蛋白结合型紫杉醇治疗的对紫杉醇过敏的子宫内膜癌或卵巢癌患者进行了回顾性研究。共识别出43例对紫杉醇过敏的卵巢癌患者（31例）或子宫内膜癌患者（12例）。所有患者在使用紫杉醇及随后的白蛋白结合型紫杉醇之前均接受了抗过敏预处理。14例患者（33%）对紫杉醇的过敏反应为轻度，25例患者（58%）为中度，4例患者（9%）为重度。43例患者中无一例对随后的白蛋白结合型紫杉醇产生过敏反应。我们的数据表明，在对紫杉醇过敏的子宫内膜癌或卵巢癌患者中使用白蛋白结合型紫杉醇是安全的，在这种临床情况下应被视为一种更优的治疗选择。
